Management of the new patient with CML in chronic phase.

about

Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.

P2860

Q37517333-43209A74-B1C1-44B5-A08A-DE10175A13F9

P2860

Management of the new patient with CML in chronic phase.

Item

http://www.wikidata.org/entity/Q38079151

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Management of the new patient with CML in chronic phase.

@en

type

Item

label

Management of the new patient with CML in chronic phase.

@en

prefLabel

Management of the new patient with CML in chronic phase.

@en

P1476

Management of the new patient with CML in chronic phase.

@en

P2093

David Marin

http://www.w3.org/2001/XMLSchema#string

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Current status of imatinib as frontline therapy for chronic myeloid leukemia.

P2888

s11899-012-0151-0

P304

37-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-012-0151-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1045846654

http://www.w3.org/2001/XMLSchema#string

P698

23381448

http://www.w3.org/2001/XMLSchema#string

Management of the new patient with CML in chronic phase.

about

P2860

P2860

Management of the new patient with CML in chronic phase.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698